Author:
Ishiyama Shiori,Hayatsu Manabu,Toriumi Taku,Tsuda Hiromasa,Watanabe Keisuke,Kasai Hirotake,Kishigami Satoshi,Mochizuki Kazuki,Mikami Yoshikazu
Abstract
AbstractNon-alcoholic steatohepatitis (NASH), caused by fat buildup, can lead to liver inflammation and damage. Elucidation of the spatial distribution of fibrotic tissue in the fatty liver in NASH can be immensely useful to understand its pathogenesis. Thus, we developed a novel serial section-3D (SS3D) technique that combines high-resolution image acquisition with 3D construction software, which enabled highly detailed analysis of the mouse liver and extraction and quantification of stained tissues. Moreover, we studied the underexplored mechanism of fibrosis progression in the fatty liver in NASH by subjecting the mice to a high-fat diet (HFD), followed by lipopolysaccharide (LPS) administration. The HFD/LPS (+) group showed extensive fibrosis compared with control; additionally, the area of these fibrotic regions in the HFD/LPS (+) group was almost double that of control using our SS3D technique. LPS administration led to an increase in Tnfα and Il1β mRNA expression and the number of macrophages in the liver. On the other hand, transforming growth factor-β1 (Tgfβ1) mRNA increased in HFD group compared to that of control group without LPS-administration. In addition, COL1A1 levels increased in hepatic stellate cell (HSC)-like XL-2 cells when treated with recombinant TGF-β1, which attenuated with recombinant latency-associated protein (rLAP). This attenuation was rescued with LPS-activated macrophages. Therefore, we demonstrated that fatty liver produced “latent-form” of TGF-β1, which activated by macrophages via inflammatory cytokines such as TNFα and IL1β, resulting in activation of HSCs leading to the production of COL1A1. Moreover, we established the effectiveness of our SS3D technique in creating 3D images of fibrotic tissue, which can be used to study other diseases as well.
Funder
Tojuro Iijima Foundation for Food Science and Technology
Japan Science and Technology Agency
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Ludwig, J., Viggiano, T. R., McGill, D. B. & Oh, B. J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55(7), 434–438 (1980).
2. Xu, G. X. et al. Activation of Kupffer cells in NAFLD and NASH: Mechanisms and therapeutic interventions. Front. Cell Dev. Biol. 11, 1199519. https://doi.org/10.3389/fcell.2023.1199519 (2023).
3. Estes, C. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J. Hepatol. 69, 896–904. https://doi.org/10.1016/j.jhep.2018.05.036 (2018).
4. Yatsuji, S. et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J. Gastroenterol. Hepatol. 24(2), 248–254. https://doi.org/10.1111/j.1440-1746.2008.05640.x (2009).
5. Tilg, H. & Moschen, A. R. Evolution of inflammation in non-alcoholic fatty liver disease : The multiple parallel hits hypothesis. Hepatology 52, 1836–1846 (2010).